No headlines found.
Prothena to Participate in Upcoming Healthcare Conferences
Business Wire (Tue, 5-Mar 4:05 PM ET)
Prothena Appoints David Ford to Newly Created Chief People Officer Position
Business Wire (Mon, 4-Mar 4:05 PM ET)
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
Business Wire (Wed, 21-Feb 4:05 PM ET)
Business Wire (Thu, 15-Feb 4:05 PM ET)
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
Business Wire (Thu, 8-Feb 4:05 PM ET)
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
Business Wire (Mon, 8-Jan 8:30 AM ET)
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Prothena PLC - trades on the NASDAQ stock market under the symbol PRTA.
As of March 28, 2024, PRTA stock price declined to $24.77 with 762,835 million shares trading.
PRTA has a beta of 0.71, meaning it tends to be less sensitive to market movements. PRTA has a correlation of 0.02 to the broad based SPY ETF.
PRTA has a market cap of $1.33 billion. This is considered a Small Cap stock.
Last quarter Prothena PLC - reported $316,000 in Revenue and -$1.26 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.04.
In the last 3 years, PRTA stock traded as high as $79.75 and as low as $21.06.
The top ETF exchange traded funds that PRTA belongs to (by Net Assets): XBI, IWM, VXF, IWO, IBB.
PRTA has underperformed the market in the last year with a price return of -48.2% while the SPY ETF gained +33.6%. PRTA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -34.6% and -13.4%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
PRTA support price is $24.22 and resistance is $26.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTA stock will trade within this expected range on the day.